Recent advancements in the gene therapy sector feature groundbreaking clinical updates involving in vivo CRISPR-Cas9 genome editing, next-generation viral vector manufacturing improvements, and successful trials targeting rare genetic disorders, inherited blindness, and blood hemoglobinopathies. Regulatory agencies continue to review new biologic license applications while emphasizing enhanced long-term patient monitoring protocols to track vector persistence and minimize potential off-target immune toxicities.